Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
41.83
+2.47 (6.28%)
At close: Jan 16, 2026, 4:00 PM EST
41.80
-0.03 (-0.07%)
After-hours: Jan 16, 2026, 7:59 PM EST
Moderna Revenue
Moderna had revenue of $1.02B in the quarter ending September 30, 2025, a decrease of -45.44%. This brings the company's revenue in the last twelve months to $2.23B, down -56.07% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$2.23B
Revenue Growth
-56.07%
P/S Ratio
7.27
Revenue / Employee
$384,828
Employees
5,800
Market Cap
16.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRNA News
- 4 days ago - Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story - Seeking Alpha
- 5 days ago - Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance. - Barrons
- 5 days ago - Moderna expects $1.9 billion in sales, trims costs forecast for 2025 - Reuters
- 5 days ago - Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Accesswire
- 10 days ago - Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross - Benzinga
- 11 days ago - America's new vaccine doctrine for children replaces data with dogma - Market Watch
- 12 days ago - Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine - Accesswire